Moreover, based on the reported hyperactive NF-kB signalling in MPN-MSCs, this pathway could serve as a target in a combined therapeutic approach against haematological malignancies, using for example a NF-kB inhibitor such as Bortezomib or Carfilzomib (66). The gene discussed is NFKB1; the disease is myeloproliferative disorder.